Post-Operative Pain Management Market is Expected to Exceed Billion By 2023 | Increasing Number of S

Page 1

Post-Operative Pain Management Market is Expected to Exceed Billion By 2023 | Increasing Number of Surgeries has Led to Grow the Industry Globally Market Research Future, a firm which specializes in market reports related to the Healthcare sector among others, recently forecasted in its report on ‘Global Post-operative Pain Management Market Research Report- Forecast to 2023’ that the market will demonstrate an exceptional CAGR while achieving good growth rapidly in the forecast period. Increasing number of surgeries and rising demand for the pain management treatment is the major reason for the growth of the market. Analgesics are habit forming drugs and can also damage the renal system, this is the major restraining factor for the market. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered. The treatment for the all types of cancer are nearly similar, thus increasing prevalence of cancer has boosted the development of the new treatments. According to Migraine Research Foundation, (2014), migraine was the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes someone with migraine. Moreover, 12% of the population including children have migraine problem. 18% of American women, 6% of men, and 10% of children experience migraines. Mostly migraine occurs at the age of 25-55. Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1246 Key Players for Global Post-operative Pain Management Market Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly Company (U.S), Pfizer (U.S), Johnson & Johnson (U.S), Purdue Pharma (U.S), Endo Pharmaceuticals Plc. (U.S), Forest Laboratories Inc. (U.S), GlaxoSmithKline Plc. (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter International Inc. (US), Valeant Pharmaceuticals International Inc. (Canada) are some of the prominent players at the forefront of competition in the Global Post-operative Pain Management Market and are profiled in MRFR Analysis. Global Post-operative Pain Management Market - Competitive Analysis Many of the top companies are launching new and novel drug treatment to increase their market. Because of side effect and habit forming property of the therapy major players are concentrating on development of better analgesic. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market. Teva Pharmaceutical Industries Ltd. is the Israeli multinational pharmaceutical company working in the development and manufacturing of the drugs. Celecoxib intravenous is the major products of the company. Company has signed a collaborative agreement with Regeneron for the development of fasinumab which is a pain management drug. In first quarter of 2017 company has accounted a revenue of $ 5.6 billion. In 2014, company has acquired Labrys Biologics. This acquisition will help to achieve its goal of becoming a global leader in pain drugs by 2020. Novartis, one of the leading pharmaceutical companies headquartered in Switzerland. In Nov 2016, company has plan a phase II trial for the NCT02961062 in the treatment of postoperative pain. They have almost completed the trials for the SAF312 in postoperative dental pain patients and company is expecting to launch the product soon. In May 2017, Novartis has sign a deal of $ 293 million with Durect for pain killer Posimir.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.